Living with or without cyclins and cyclin-dependent kinases
Open accessThe DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Entry into, progression through, and exit from the G1 phase of the mammalian cell cycle in response to extracellular mitogenic cues are presumed to be governed by cyclin-dependent kinases (Cdks) regulated by the D-type and E-type cyclins. Studies performed over more than a decade have supported the view that these holoenzymes are important, if not required, for these processes. However, recent experiments in which the genes encoding all three D-type cyclins, the two E-type cyclins, cyclin D-dependent Cdk4 and Cdk6, or cyclin E-dependent Cdk2 have been disrupted in the mouse germ line have revealed that much of fetal development occurs normally in their absence. Thus, none of these genes is strictly essential for cell cycle progression. To what extent is the prevailing dogma incorrect, and how can the recent findings be reconciled with past work?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the high frequency of mutations epistatically targeting the RB signaling pathway in cancer cells, inactivation of the individual cyclin D, Cdk4/6, and Ink4a genes in mice, while leading to specific developmental defects when disrupted alone or in combination, established that their functions were nonessential for the cell cycle per se (62-64).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it may well prove that mutations affecting other cell cycle regulators, such as amplification of cyclin E, loss of p27Kip1 or p21Cip1 and activation of CDK2 would bypass the requirement of tumor cells for CDK4/6 activity, thereby also conferring de novo resistance (62-64).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [63]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370 · cited 1×
“…the idea that mutant " cancer stem cells, " rather than their differentiated progeny that may make up the bulk of a tumor, are the only cells strictly responsible for durable tumor maintenance and, in turn, for resistance to therapy (Reya et al. 2001; Taipale and Beachy 2001; Al-Hajj et al. 2003).”
BackgroundStem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738 · cited 2×
“The cells that give rise to many cancers have both the self-renewal and differentiating capacities of tissue stem cells, raising the idea that mutant “cancer stem cells,” rather than their differentiated progeny that may make up the bulk of a tumor, are the only cells strictly responsible for durable tumor maintenance…”
BackgroundCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“The AKT kinase controls the subcellular localization of Cip/Kip proteins as well (Liang et al. 2002; Shin et al. 2002; Viglietto et al. 2002), providing yet another avenue for cyclin E–Cdk2 regulation in response to extracellular cues.”
BackgroundSelf-citationA new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 2×
“1994); conversely, attenuation of Cdk4 activity by polypeptide inhibitors of the INK4 gene family (Serrano et al. 1993) or by Cdk4-selective drugs (Tetsu and McCormick 2003) results in G1-phase arrest and cell cycle exit.”
BackgroundInhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243 · cited 6×
“1993), and by induction of polypeptide inhibitors of the Cip/Kip family in many physiologic settings (Sherr and Roberts 1995) result in G1-phase arrest.”
BackgroundInfluentialSelf-citationG1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674 · cited 1×
“If this occurs before the G1/S boundary, cells exit the cycle without replicating their DNA, but if it occurs afterward, cells complete mitosis and exit from the cycle in the next G1 interval (Matsushime et al. 1994; Sherr 1994).”
BackgroundSelf-citationCYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors
Morgan, D. O. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.261 · Cited by 2,259 · cited 3×
“The relevant proteins include three D-type cyclins (D1, D2, and D3) that, in different combinations, bind to, and allosterically regulate, one of two Cdk subunits, Cdk4 and Cdk6, as well as the E-type cyclins (E1 and E2), which, in analogous fashion, govern the activity of a single catalytic subunit, Cdk2 (Morgan 1997…”
BackgroundInfluentialGlycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130 · cited 2×
“…GSK-3, an enzyme that is inhibited by the phosphatidylinositol 3-kinase/AKT signaling pathway , in determining the stability of cyclin E implies that its life history, like that of cyclin D1 (Diehl et al. 1998), can be directly influenced by at least one mitogen-dependent kinase signaling cascade.”
BackgroundSelf-citationPolyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., & Koff, A. (1994) · Genes & Development · doi:10.1101/gad.8.1.9 · Cited by 1,954 · cited 1×
“, two potent inhibitors of Cdk2 (Polyak et al. 1994; Reynisdottir et al. 1995; Sherr and Roberts 1995).”
Self-citationCyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614 · cited 2×
“In continuously dividing cells, cyclin D1 exits the cell nucleus during S phase, and its turnover is accelerated throughout this interval (Baldin et al. 1993; Diehl et al. 1998), but Rasdependent cyclin D1 synthesis and its stabilization in G2 phase allow it to reaccumulate before cells divide (Guo…”
Background
Research works printed but not linked: 1
- Resnitzky, D., Gossen, M., Bujard, H., and Reed, S.I. 1994. Ac- celeration of the G1/S phase transition by expression of cy- clins D1 and E with an inducible system. Mol. Cell. Biol. 14: 1669-1679.
Cited by
Items 201–300 of 1,000
Neocortical neurogenesis: morphogenetic gradients and beyond
Caviness, V. S., Nowakowski, R. S., & Bhide, P. G. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.05.003 · Cited by 79
The cyclin D1b splice variant: an old oncogene learns new tricks.
Knudsen, K. E. (2006) · Cell Division · doi:10.1186/1747-1028-1-15 · Cited by 93
“In its hypophosphorylated state, RB exerts potent anti-proliferative action through its ability to form transcriptional repressor complexes on the promoters of genes required for S-phase progression [44,2,45].”
BackgroundSun, B., Mason, S., Wilson, R. C., Hazard, E. S., Wang, Y., Fang, R., Wang, Q., Yeh, E. S., Yang, M., Roberts, T. M., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0953-9 · Cited by 80
Cornils, H., Kohler, R. S., Hergovich, A., & Hemmings, B. A. (2011) · Cell Cycle · doi:10.4161/cc.10.12.15826 · Cited by 83
Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer
Caldon, C. E., Sutherland, R. L., & Musgrove, E. A. (2010) · Cell Cycle · doi:10.4161/cc.9.10.11474 · Cited by 86
Vigneron, A., Cherier, J., Barré, B., Gamelin, E., & Coqueret, O. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602492200 · Cited by 73
Policing Cancer: Vitamin D Arrests the Cell Cycle
Bhoora, S., & Punchoo, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239296 · Cited by 81
“Once the cell traverses the G1/G0 restriction point, it is committed to cell division and will undergo mitosis [24].”
BackgroundKoyama‐Nasu, R., Nasu‐Nishimura, Y., Todo, T., Ino, Y., Saito, N., Aburatani, H., Funato, K., Echizen, K., Sugano, H., Haruta, R., et al. (2012) · Oncogene · doi:10.1038/onc.2012.399 · Cited by 86
Han, W., Wang, L., Zhang, L., Wang, Y., & Li, Y. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.131 · Cited by 75
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease
Liu, N.-A., Araki, T., Cuevas-Ramos, D., Hong, J., Ben-Shlomo, A., Tone, Y., Tone, M., & Melmed, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1606 · Cited by 71
Kim, Y. J., Yoon, S. Y., Kim, J., Choi, S. C., Lim, J., Kim, J. H., Song, E. Y., Lee, H. G., Choi, I., & Kim, J. W. (2008) · International Journal of Cancer · doi:10.1002/ijc.23945 · Cited by 79
“D-type cyclins are believed to serve as links between the extracellular environment and the core cell cycle machinery because the levels of D cyclins are controlled by the extracellular mitogenic environment, unlike other cyclins that are periodically induced during the cell cycle progression.(47,48) We thought that N…”
BackgroundCell cycle markers in clinical oncology
Williams, G. H., & Stoeber, K. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.10.005 · Cited by 80
CDC25A Phosphatase: a Rate-Limiting Oncogene That Determines Genomic Stability
Ray, D., & Kiyokawa, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5983 · Cited by 75
“High levels of functional redundancy seem to exist among the components of the CDK system, according to remarkably mild developmental phenotypes of mice deficient for each component, such as cyclin D1, D2, D3, E1, E2, CDK2, CDK4, or CDK6 null mice (2).”
Rojas, C. A., Eloy, N. B., Lima, M. D. F., Rodrigues, R. L., Franco, L. O., Himanen, K., Beemster, G. T. S., Hemerly, A. S., & Ferreira, P. C. G. (2009) · Plant Molecular Biology · doi:10.1007/s11103-009-9525-7 · Cited by 79
“In eukaryotes, regulation of cell cycle progression relies on the function of CDKs (Sherr and Roberts 2004).”
BackgroundTargeting CDK4/6 in breast cancer
Shanabag, A., Armand, J., Son, E., & Yang, H. W. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01395-3 · Cited by 80
“The INK4 family of CDK4/6 inhibitors (p16, p15, p18 and p19) bind to the catalytic pocket of CDK4/6, competing with cyclin D and blocking CDK4/6 kinase activity 26 .”
Reddy, L. H., Renoir, J., Marsaud, V., Lepêtre‐Mouelhi, S., Desmaële, D., & Couvreur, P. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900099e · Cited by 74
Klier, M., Anastasov, N., Hermann, A., Meindl, T., Angermeier, D., Raffeld, M. A., Fend, F., & Quintanilla‐Martínez, L. (2008) · Leukemia · doi:10.1038/leu.2008.213 · Cited by 79
Functional Evolution of Cyclin-Dependent Kinases
Doonan, J. H., & Kitsios, G. D. (2009) · Molecular Biotechnology · doi:10.1007/s12033-008-9126-8 · Cited by 78
Redundancy: A Critical Obstacle to Improving Cancer Therapy
Lavi, O. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3256 · Cited by 68
“Thus, most of these elements can be compensated for by others, such aswhenCdk2 compensates for Cdk4, 6, and 1, due to their redundant functions in cell-cycle feedback loops (31).”
BackgroundThe MicroRNA Pathway Plays a Regulatory Role in Stem Cell Division
Shcherbata, H. R., Hatfield, S. D., Ward, E. J., Reynolds, S., Fischer, K. A., & Ruohola‐Baker, H. (2006) · Cell Cycle · doi:10.4161/cc.5.2.2343 · Cited by 81
Charrier, C., Coronas, V., Fombonne, J., Roger, M., Jean, A., Krantic, S. M., & Moyse, E. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.10.046 · Cited by 74
Hao, W., Takano, T., Guillemette, J., Papillon, J., Ren, G., & Cybulsky, A. V. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511744200 · Cited by 79
Singh, R., Bhardwaj, V. K., Das, P., & Purohit, R. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1696709 · Cited by 72
Tu, Y., Wu, W., Wu, T., Cao, Z., Wilkins, R. J., Toh, B. H., Cooper, M. E., & Chai, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609623200 · Cited by 73
Transcriptome sequencing of neonatal thymic epithelial cells
St-Pierre, C., Brochu, S., Vanegas, J. R., Dumont-Lagacé, M., Lemieux, S., & Perreault, C. (2013) · Scientific Reports · doi:10.1038/srep01860 · Cited by 87
Growth factor control of pancreatic islet regeneration and function
Assmann, A., Hinault, C., & Kulkarni, R. N. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00468.x · Cited by 68
“initiation of a transcriptional program required for entering the S phase of the cell cycle (64).”
BackgroundChen, Z., & McKnight, S. L. (2007) · Cell Cycle · doi:10.4161/cc.6.23.5041 · Cited by 69
Jeong, J.-H., Kang, S.-S., Park, K.-K., Chang, H.-W., Magae, J., & Chang, Y.-C. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1159 · Cited by 73
“Cell cycle progression in eukaryotic cells is highly ordered and tightly regulated by the activity of the CDK-cyclin complexes (2, 3).”
BackgroundSmad3 phosphorylation by cyclin-dependent kinases
LIU, F. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.010 · Cited by 71
Immunomodulatory Roles of Cell Cycle Regulators
Laphanuwat, P., & Jirawatnotai, S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00023 · Cited by 71
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
Garrido-Castro, A. C., & Goel, S. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0232-0 · Cited by 69
“In other cases, genes for endogenous CDK inhibitors are deleted, facilitating unconstrained CDK activity [2].”
BackgroundPapadimitriou, M., Pazaiti, A., Iliakopoulos, K., Markouli, M., Michalaki, V., & PAPADIMITRIOU, C. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119346 · Cited by 78
Yde, C. W., & Issinger, O. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.6.1397 · Cited by 82
Rokkaku, T., Kimura, R., Ishikawa, C., Yasumoto, T., Senba, M., Kanaya, F., & Mori, N. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2019 · Cited by 72
Clappier, E., Cuccuini, W., Cayuela, J., Vecchione, D., Baruchel, A., Dombret, H., Sigaux, F., & Soulier, J. (2005) · Leukemia · doi:10.1038/sj.leu.2404008 · Cited by 71
Cdk2: a key regulator of the senescence control function of Myc
Hydbring, P., & Larsson, L. (2010) · Aging · doi:10.18632/aging.100140 · Cited by 81
“Since Cdk2 function in the cell cycle is compensated by other Cdks during development [15], this is a unique, non-redundant role of Cdk2.”
BackgroundSCAPER, a novel cyclin A–interacting protein that regulates cell cycle progression
Tsang, W. Y., Wang, L., Chen, Z., Sánchez, I., & Dynlacht, B. D. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200701166 · Cited by 78
“Several cyclin/Cdk complexes have been implicated in cell cycle control (Sherr and Roberts, 2004).”
BackgroundTranscription factor FOXM1c is repressed by RB and activated by cyclin D1/Cdk4
Wierstra, I., & Alves, J. (2006) · Biological Chemistry · doi:10.1515/bc.2006.119 · Cited by 68
“The cell cycle is controlled by the consecutive action of different cyclin/Cdk complexes, the activity of which is tightly regulated by diverse mechanisms (Sherr and Roberts, 1999, 2004; Obaya and Sedivy, 2002; Ciemerych and Sicinski, 2005).”
BackgroundInfluentialCyclin D2 Translocates p27 out of the Nucleus and Promotes Its Degradation at the G0-G1 Transition
Susaki, E., Nakayama, K., & Nakayama, K. I. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00862-06 · Cited by 66
“The activities of these complexes are regulated by various mechanisms, including inhibition by CDK inhibitors (CKIs) (70).”
BackgroundBockstaele, L., Kooken, H., Libert, F., Paternot, S., Dumont, J. E., de Launoit, Y., Roger, P. P., & Coulonval, K. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02006-05 · Cited by 78
“Cyclin-dependent kinase 4 (CDK4) and CDK6 act in G1 phase as a master integrator of various mitogenic and antimitogenic signals (76, 80).”
BackgroundHuman Pancreatic β-Cell G1/S Molecule Cell Cycle Atlas
Fiaschi-Taesch, N. M., Kleinberger, J. W., Salim, F. G., Troxell, R., Wills, R., Tanwir, M., Casinelli, G., Cox, A. E., Takane, K. K., Scott, D. K., et al. (2013) · Diabetes · doi:10.2337/db12-0777 · Cited by 70
Cyclin D/CDK4/6 activity controls G1 length in mammalian cells
Dong, P., Zhang, C., Parker, B., You, L., & Mathey-Prévôt, B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0185637 · Cited by 73
Thyroid hormones and their receptors in the regulation of cell proliferation.
Puzianowska-Kuznicka, M., Pietrzak, M., Turowska, O., & Nauman, A. (2006) · Acta Biochimica Polonica · doi:10.18388/abp.2006_3292 · Cited by 68
“In response to mitogenic signals cyclins D1, D2, and D3 (Sherr, 1993; Sherr & Roberts, 2004 ) form complexes with cyclindependent kinases cdk4 or cdk6 (Matsushime et al., 1992; Meyerson & Harlow, 1994).”
BackgroundIn Vitro and In Vivo Anti-Melanoma Effects of Ciglitazone
Botton, T., Puissant, A., Bahadoran, P., Annicotte, J., Fajas, L., Ortonne, J. ‐., Gozzerino, G., Zamoum, T., Tartare‐Deckert, S., Bertolotto, C., et al. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.346 · Cited by 68
“…with a dramatic reduction of cyclin D1 expression, a marked increase in the expression of cyclin-dependent kinase inhibitor p21Cip1/Waf1, and hypophosphorylation of pRb. Cyclin D1 is one of the cyclins that may affect the G1 phase of the cell cycle in different tumors (Sherr and Roberts, 2004).”
BackgroundWang, Y., Zhou, Y., Zhou, H., Jia, G., Liu, J., Han, B., Cheng, Z., Jiang, H., Pan, S., & Sun, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043826 · Cited by 68
Mukherji, A., Janbandhu, V. C., & Kumar, V. (2006) · Biochemical Journal · doi:10.1042/bj20061091 · Cited by 68
Fusté, N. P., Guasch, M., Guillen, P., Anerillas, C., Cemeli, T., Pedraza, N., Ferrezuelo, F., Encinas, M., Moralejo, M., & Garí, E. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.01.090 · Cited by 68
Molenaar, J. J., Koster, J., Ebus, M. E., van Sluis, P., Westerhout, E. M., de Preter, K., Gisselsson, D., Øra, I., Speleman, F., Caron, H. N., et al. (2012) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20926 · Cited by 63
Thompson, M. D., Thompson, H. J., Brick, M. A., McGinley, J. N., Jiang, W., Zhu, Z., & Wolfe, P. (2008) · Journal of Nutrition · doi:10.3945/jn.108.094557 · Cited by 67
Ah Receptor–Mediated Suppression of Liver Regeneration through NC-XRE–Driven p21Cip1 Expression
Jackson, D. P., Li, H., Mitchell, K. A., Joshi, A., & Elferink, C. J. (2014) · Molecular Pharmacology · doi:10.1124/mol.113.089730 · Cited by 74
“Hyperphosphorylation and concomitant inactivation of the Rb protein is considered to be the major function of the G1and S-phase CDKs (Sherr and Roberts, 2004).”
BackgroundHaploinsufficient tumor suppressor genes.
Inoue, K., & Fry, E. A. (2017) · PubMed · Cited by 85
Inoue, K., Mallakin, A., & Frazier, D. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210226 · Cited by 75
Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities
Zabihi, M., Lotfi, R., Yousefi, A., & Bashash, D. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04135-6 · Cited by 67
“(2010) CDK6 Cyclin D G1 phase, Rb/E2F transcription Malumbres and Barbacid (2009) and Sherr and Roberts (2004)”
BackgroundAlagbala, A. A., McRiner, A. J., Borstnik, K., Labonte, T., Chang, W., D’Angelo, J. G., Posner, G. H., & Foster, B. A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060803i · Cited by 68
Cyclin D1 Gene Ablation Confers Neuroprotection in Traumatic Brain Injury
Kabadi, S. V., Stoica, B. A., Loane, D. J., Byrnes, K. R., Hanscom, M., Cabatbat, R. M., Tan, M. T., & Faden, A. I. (2012) · Journal of Neurotrauma · doi:10.1089/neu.2011.1980 · Cited by 66
“In addition, D-type cyclins modulate cyclin E and indirectly affect CDK2 activity (Sherr and Roberts, 2004), by titration of the endogenous CDK inhibitors p27Cip1 and p27Kip1 from cyclin E/CDK2 complexes (Cheng et al., 1998; Reynisdottir et al., 1995; Swanton, 2004).”
BackgroundInfluentialBae, W. K., Kang, K., Yu, J. H., Yoo, K. H., Factor, V. M., Kaji, K., Matter, M. S., Thorgeirsson, S. S., & Hennighausen, L. G. (2014) · The FASEB Journal · doi:10.1096/fj.14-261537 · Cited by 71
“Cdkn2aandCdkn2bgenesencodep16andp15 inhibitorsof the G1/S phase of the cell cycle (26), and derepression of Cdkn2a has been suggested to induce cell death through downstream targets of p53, including p21 and Wig1 (27).”
BackgroundAlbanese, C., Alzani, R., Amboldi, N., Avanzi, N. R., Ballinari, D., Brasca, M. G., Festuccia, C., Fiorentini, F., Locatelli, G., Pastori, W., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0190 · Cited by 66
Novel Molecular Markers for Breast Cancer
Inoue, K., & Fry, E. A. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s38394 · Cited by 70
Maintenance of genome integrity and active homologous recombination in embryonic stem cells
Choi, E.-H., Yoon, S., Koh, Y. E., Seo, Y., & Kim, K. P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0481-2 · Cited by 66
Synthesis of Imidazothiazole–Chalcone Derivatives as Anticancer and Apoptosis Inducing Agents
Kamal, Ä., Dastagiri, D., Ramaiah, M. J., Reddy, J., Bharathi, E. V., Chatla, S., Pushpavalli, S. N. C. V. L., Pal, D., & Pal‐Bhadra, M. (2010) · ChemMedChem · doi:10.1002/cmdc.201000346 · Cited by 65
Wiesner, T., Obenauf, A. C., Cota, C., Fried, I., Speicher, M. R., & Cerroni, L. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.369 · Cited by 65
“High levels of p27 arrest the cell cycle by inhibiting cyclin E-dependent kinases, but low levels of p27 drive the cell cycle by stabilizing cyclin D-dependent kinases (Sherr and Roberts, 2004).”
BackgroundIκB Kinase α Regulates Subcellular Distribution and Turnover of Cyclin D1 by Phosphorylation
Kwak, Y.-T., Li, R., Becerra, C. R., Tripathy, D., Frenkel, E. P., & Verma, U. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506206200 · Cited by 64
CDC25A targeting by miR-483-3p decreases CCND–CDK4/6 assembly and contributes to cell cycle arrest
Bertero, T., Gastaldi, C., Bourget, I., Mari, B. P., Meneguzzi, G., Barbry, P., Ponzio, G., & Rezzonico, R. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.5 · Cited by 67
“The activity of CDKs can be blocked by natural inhibitors, CKI, belonging either to the INK4 (p16, p15, p18, p19) or the CIP (p21, p27, p57) families.(2) MiRNAs are small non-coding RNAs that post-transcriptionally repress gene expression, mainly through binding to the 30-”
BackgroundFunctional characterization of human PFTK1 as a cyclin-dependent kinase
Shu, F., Lv, S., Qin, Y., Ma, X., Wang, X., Peng, X., Luo, Y., Xu, B.-E., Sun, X., & Wu, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703327104 · Cited by 65
Garay, J. P., Karakas, B., Abukhdeir, A. M., Cosgrove, D., Gustin, J. P., Higgins, M. J., Konishi, H., Konishi, Y., Lauring, J. D., Mohseni, M., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3112 · Cited by 72
“Additionally, we examined the expression of cyclin E and cyclin D1, two key regulators of cell cycle progression [60] After 48 hours of treatment with R1881 in the presence of EGF, cyclin E levels were not altered in ARIBE or control cell lines (data not shown), but levels of cyclin D1 were decreased by nearly 50% com…”
BackgroundLow concentration of BPA induces mice spermatocytes apoptosis via GPR30
Wang, C., Zhang, J., Li, Q., Zhang, T., Deng, Z., Lian, J., Jia, D., Li, R., Zheng, T., Ding, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16923 · Cited by 69
“Cyclin D1 promotes the G1 to S phase transition in cell cycle, and it plays a specific role in mitosis [57].”
BackgroundColle, D., Farina, M., Ceccatelli, S., & Raciti, M. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9916-0 · Cited by 71
Libertini, S., Iacuzzo, I., Perruolo, G., Scala, S., Ieranò, C., Franco, R., Halldén, G., & Portella, G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0200 · Cited by 65
Majumder, P., Trujillo, C. A., Lopes, C. G., Resende, R. R., Gomes, K. N., Yuahasi, K. K., Britto, L. R. G., & Ulrich, H. (2007) · Purinergic Signalling · doi:10.1007/s11302-007-9074-y · Cited by 67
“Various combinations of Dtype cyclins are expressed in different cell types, whereas cyclin E-cdk2 complexes are ubiquitously expressed [177].”
BackgroundSalpeter, S. J., Klochendler, A., Weinberg-Corem, N., Porat, S., Granot, Z., Shapiro, A. M. J., Magnuson, M. A., Eden, A., Grimsby, J., Glaser, B., et al. (2011) · Endocrinology · doi:10.1210/en.2010-1372 · Cited by 64
Sun, Y., Wang, P., Yang, W., Shan, Y., Zhang, Q., & Wu, H. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1529121 · Cited by 63
Lin, S.-Y., Lai, W.-W., Chou, C.-C., Kuo, H.-M., Li, T.-M., Chung, J.-G., & Yang, J.-H. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000232297.99160.9e · Cited by 63
D-type cyclins control cell division and developmental rate during Arabidopsis seed development
Collins, C., Dewitte, W., & Murray, J. A. H. (2012) · Journal of Experimental Botany · doi:10.1093/jxb/ers015 · Cited by 66
Ding, Z., Li, R., Zhang, Q., Wang, Y., Jiang, Y., Meng, Q., Xi, Q., & Wu, G. (2019) · Cancer Medicine · doi:10.1002/cam4.2152 · Cited by 67
Gizard, F., Nomiyama, T., Zhao, Y., Findeisen, H. M., Heywood, E. B., Jones, K. L., Staels, B., & Bruemmer, D. (2008) · Circulation Research · doi:10.1161/circresaha.108.186205 · Cited by 62
Han, S., Herrmann, A., Yang, J., Iwasaki, R., Sakamoto, T., Desvoyes, B., Kimura, S., Gutiérrez, C., Kim, E., & Torii, K. U. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.01.014 · Cited by 62
Interweaving the Cell Cycle Machinery with Cell Differentiation
Miller, J. P., Yeh, N., Vidal, A., & Koff, A. (2007) · Cell Cycle · doi:10.4161/cc.6.23.5042 · Cited by 62
Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non-small Cell Lung Cancer
Duncavage, E. J., Goodgame, B. W., Sezhiyan, A., Govindan, R., & Pfeifer, J. D. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f3909d · Cited by 65
Magiera‐Mularz, K., Tomala, M. D., Kubica, K., Cesare, V. D., Trost, M., Zieba, B. J., Kachamakova‐Trojanowska, N., Leś, M., Dubin, G., Holak, T. A., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.03.002 · Cited by 62
Mirk Regulates the Exit of Colon Cancer Cells from Quiescence
Jin, K., Ewton, D. Z., Park, S., Hu, J., & Friedman, E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.035519 · Cited by 65
A systems biology dynamical model of mammalian G 1 cell cycle progression
Haberichter, T., Mädge, B., Christopher, R. A., Yoshioka, N., Dhiman, A., Miller, R., Gendelman, R., Aksenov, S. V., Khalil, I. G., & Dowdy, S. F. (2007) · Molecular Systems Biology · doi:10.1038/msb4100126 · Cited by 62
“In contrast, p27 genetic deletions have no effect on the timing of pRb inactivation (Pagano and Jackson, 2004; Sherr and Roberts, 2004).”
BackgroundPiwil1 Regulates Glioma Stem Cell Maintenance and Glioblastoma Progression
Huang, H., Yu, X., Han, X., Jing, H., Zhao, J., Bebek, G., Bao, S., Prayson, R. A., Khalil, A. M., Jankowsky, E., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108522 · Cited by 61
“Silencing Piwil1 also reduced expression of cyclin D2 (CCND2) (Figures 5A and 5B), which regulates G1/S transition (Sherr and Roberts, 2004).”
BackgroundJerafi-Vider, A., Bassi, I., Moshe, N., Tevet, Y., Hen, G., Splittstoesser, D., Shin, M., Lawson, N. D., & Yaniv, K. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109255 · Cited by 64
“The length of the G1 stage is known to be controlled by cell cycle inhibitors such as p21 and p27, which suppress cyclin/cyclin-dependent kinase (CDK) complex activity (Satyanarayana and Kaldis, 2009; Sherr and Roberts, 1999, 2004).”
BackgroundThe AR dependent cell cycle: Mechanisms and cancer relevance
Schiewer, M. J., Augello, M. A., & Knudsen, K. E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.033 · Cited by 64
“Transitions into and within the cell cycle are controlled by cyclin/cyclin-dependent kinase (cdk) complexes, which act sequentially to maintain ordered progression from G1 to mitosis (Lee and Sicinski, 2006; Malumbres and Barbacid, 2007; Sherr and Roberts, 2004).”
BackgroundVargas, T. R., Boudoukha, S., Simon, A., Souidi, M., Cuvellier, S., Pinna, G., & Polesskaya, A. (2013) · Oncogene · doi:10.1038/onc.2013.252 · Cited by 61
HIV-1 mRNA 3′ End Processing Is Distinctively Regulated by eIF3f, CDK11, and Splice Factor 9G8
Valente, S. T., Gilmartin, G. M., Venkataraman, K., Arriagada, G., & Goff, S. P. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.10.004 · Cited by 61
Gomez, L. A., Pozas, A. D. L., Reiner, T., Burnstein, K. L., & Perez‐Stable, C. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0727 · Cited by 64
“We used antibodies specific for cyclin B1 (GNS1), CDK1 (17), Bax (N-20), AR (N-20),Mcl-1 (S-19), survivin (FL-142), p53 (DO-1; SantaCruz Biotechnology), poly(ADP-ribose) polymerase (PARP; C210), E-cadherin (clone 36), Bcl-xL (polyclonal; BD Biosciences PharMingen), cleaved PARP (Asp(214)), cleaved caspase-3 (9661), X-…”
BackgroundMethodButt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-78818-0_12 · Cited by 59
Karpurapu, M., Wang, D., Quyền, Đ. V., Kim, T., Kundumani‐Sridharan, V., Pulusani, S., & Rao, G. N. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.063727 · Cited by 66
Slotta‐Huspenina, J., Koch, I., de Leval, L., Keller, G., Klier, M., Bink, K., Kremer, M., Raffeld, M. A., Fend, F., & Quintanilla‐Martínez, L. (2012) · Haematologica · doi:10.3324/haematol.2011.055715 · Cited by 61
Cytoplasmic-Nuclear Trafficking of G1/S Cell Cycle Molecules and Adult Human β-Cell Replication
Fiaschi-Taesch, N. M., Kleinberger, J. W., Salim, F. G., Troxell, R., Wills, R., Tanwir, M., Casinelli, G., Cox, A. E., Takane, K. K., Srinivas, H., et al. (2013) · Diabetes · doi:10.2337/db12-0778 · Cited by 58
Ramos‐García, P., González‐Moles, M. Á., González‐Ruiz, L., Ruiz‐Ávila, I., Ayén, Á., & Montoya, J. A. G. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.06.007 · Cited by 66
MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors
Chen, X., Burkhardt, D. B., Hartman, A. A., Hu, X., Eastman, A. E., Sun, C., Wang, X., Zhong, M., Krishnaswamy, S., & Guo, S. (2019) · Nature Communications · doi:10.1038/s41467-019-13666-5 · Cited by 58
Tong, Y., Li, F. Y., Lu, Y., Cao, Y., Gao, J., & Liu, J. (2013) · Molecular Reproduction and Development · doi:10.1002/mrd.22267 · Cited by 58
Cell cycle machinery in oncology: A comprehensive review of therapeutic targets
Cavalu, S. D., Abdelhamid, A. M., Saber, S., Elmorsy, E. A., Hamad, R. S., Abdel‐Reheim, M. A., Yahya, G., & Salama, M. M. (2024) · The FASEB Journal · doi:10.1096/fj.202400769r · Cited by 65
“24 Amplification, mutation, and overexpression of cyclin D are major contributors to this pathway dysfunction.”
BackgroundDu, X., Li, Y., Wu, C., Zhou, J., Han, Y., Sui, H., Wei, X.-L., Liu, L., Huang, P., Yuan, H.-H., et al. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.01.013 · Cited by 58
p21Cip1 modulates arterial wound repair through the stromal cell–derived factor-1/CXCR4 axis in mice
Olive, M., Mellad, J. A., Beltran, L. E., Ma, M., Cimato, T., Noguchi, A. C., San, H., Childs, R., Kovacic, J. C., & Boehm, M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci31244 · Cited by 59
“The Cip/Kip proteins (p21Cip1, p27Kip1, and p57Kip2) bind to and alter the activities of cyclin D–, cyclin E–, and cyclin A–dependent kinases in quiescent cells (11, 12).”
BackgroundThe genomic repertoire for cell cycle control and DNA metabolism in S. purpuratus
Fernàndez-Guerra, A., Aze, A., Morales, J., Mulner‐Lorillon, O., Cosson, B., Cormier, P., Bradham, C. A., Adams, N. L., Robertson, A., Marzluff, W. F., et al. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.09.012 · Cited by 62
“…activate CDKs by changing the conformation at their catalytic sites, but also contribute to the selection of CDK substrates, subcellular localization, and regulation of protein stability (reviewed in Malumbres and Barbacid, 2005; Murray, 2004; Sanchez and Dynlacht, 2005; Sherr and Roberts, 2004).”
BackgroundCyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma
Casson, A. G., Zheng, Z., Evans, S. C., Geldenhuys, L., van Zanten, S. V., Veugelers, P. J., Porter, G. A., & Guernsey, D. L. (2005) · Cancer · doi:10.1002/cncr.21229 · Cited by 64
ZAC1 target genes and pituitary tumorigenesis
Theodoropoulou, M., Stalla, G. K., & Spengler, D. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.01.033 · Cited by 58
Metadata
- Authors
- Sherr, C. J., & Roberts, J. M.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2004-11-15
- Volume
- 18
- Issue
- 22
- Pages
- 2699-2711
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2152107294
- Cited by
- 1,089
- References
- 115
- Citations by year
- 2026: 13 · 2025: 36 · 2024: 48 · 2023: 38 · 2022: 34 · 2021: 42 · 2020: 49 · 2019: 50 · 2018: 36 · 2017: 35 · 2016: 42 · 2015: 51 · 2014: 47 · 2013: 52 · 2012: 62
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Keywords
- cyclin-dependent kinases, cyclins, D-type cyclins, G1 phase, cell cycle progression, CDK4, CDK6, CDK2, cyclin E, cyclin D, fetal development, mitogenic signaling
- MeSH terms
- Animals, Cell Cycle, Humans, Signal Transduction, Cyclins, Mice, Knockout, Cyclin-Dependent Kinases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.